A strategy to eradicate well-developed Krebs-2 ascites in mice

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• DNA Repair Mechanisms

Background:

• Krebs-2 ascites is a murine cancer model.
• Tumor-initiating stem cells (TISCs) possess the ability to internalize extracellular double-stranded DNA (dsDNA).
• Internalized dsDNA can disrupt DNA repair processes within TISCs, leading to cell death or loss of tumorigenicity.

Purpose of the Study:

• To describe a novel therapeutic strategy for eradicating Krebs-2 ascites in experimental mice.
• To leverage the dsDNA uptake capability of Krebs-2 TISCs to induce cell death or eliminate their tumorigenic potential.
• To optimize a multi-step treatment regimen involving cyclophosphamide and dsDNA.

Main Methods:

• A 3-step therapeutic regimen was employed.
• Timed injections of cyclophosphamide (CP) were administered to synchronize ascites cells in late S/G2/M phases.
• Treatment with a dsDNA-based preparation was given post-CP injection to interfere with Nucleotide Excision Repair (NER) and Homologous Recombination (HR) pathways.
• A final combination treatment of CP and dsDNA was administered during apoptotic destruction and cell cycle re-entry.

Main Results:

• The described regimen effectively eradicated Krebs-2 ascites in experimental mice.
• The strategy successfully targeted and eliminated Krebs-2 tumor-initiating stem cells (TISCs).
• The treatment induced cell death and compromised the tumorigenic properties of ascites cells by interfering with DNA repair.

Conclusions:

• The developed 3-step strategy offers a potential cure for Krebs-2 ascites.
• Exploiting TISC-specific dsDNA uptake and DNA repair interference presents a promising therapeutic approach.
• This regimen ensures the elimination of viable cells, including TISCs, preventing cancer recurrence.